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Introduction
Several biologic agents have become available for the treat-
ment of systemic juvenile idiopathic arthritis (SJIA) over
the last decade. Prescription strategies may depend on dis-
ease course, which is heterogeneous and other factors
including the availability of biological agents, ongoing clin-
ical trials and National marketing authorizations.
Objectives
To assess drug survival of biological agents in SJIA patients
and to describe reasons for switching or discontinuating
biologic treatment.
Methods
A retrospective observational study was conducted on
SJIA patients treated in a French pediatric rheumatology
reference center using the CEMARA register, a nation-
wide information system for rare diseases. We included
patients who started biotherapy between 2005 and 2012
with a follow-up of at least 6 months after treatment
initiation. Factors for switching or discontinuation of a
biological agent were assessed.
Results
74 SJIA patients were included, with 41 female and 33 male
subjects and a median age of 4.1 years at diagnosis [range 9
months to 15.1 years]. Median disease duration before
starting the first biological agent was 17.3 months [range
1.7 to 107]. The cumulative follow up on biologics repre-
sented 266.5 patient-years. Concomitant treatment
included non-steroidal anti-inflammatory drugs in 94%, sys-
temic steroids in 84% and disease-modifying anti-rheumatic
drugs [7 methotrexate, 1 hydroxychloroquine, 1 lefluno-
mide] in 12% at onset of biologic treatment. First-line
biological agents were anakinra (ANA) in 45 patients, cana-
kinumab (CAN) in 13, tocilizumab (TCZ) in 3, etanercept
(ETA) in 12 and adalimumab (ADA) in 1 patient. At
3 months, drug survival for ANA versus CAN versus TCZ
versus ETA as first-line biological therapy was 82% versus
100% versus 100% versus 67% percent, respectively. At
12/24 months, drug survival for ANA was 55/55%, for
CAN 76/69%, for TCZ 67/67% and for ETA 58/58%,
respectively. With first-line treatment, clinical remission
was obtained in 55/69/67/9% of ANA/CAN/TCZ/ETA
treated patients, respectively.
35/15/33/63% of ANA/CAN/TCZ/ETA treated patients
switched to a second biological agent. At 3/12/24 months
of second-line treatment, drug survival was 80/20/20% for
ANA, 67/67/33% for CAN, 100/100/40% for TCZ and
67/67/33% for ETA. One patient was switched from ETA
to abatacept with a drug survival of 73.6 months. 26% and
4% of the patients experienced a switch to a third and
fourth biological agent, respectively. In total, 64% of the
patients achieved clinical remission with one or up to four
biological agents.
Reasons for switching treatment were lack of efficacy in
37%, adverse events in 21%, loss of response to treatment
in 32% and patient’s/parent’s choice in 10%. Biological
treatment was stopped in 10.8% of the patients due to
inactive disease after a median time of 35.1 months
[range 9 to 69 months]. Relapse of symptoms occurred in
42% after cessation of biotherapy.
Conclusion
Switching to a second or third biological agent is an
appropriate approach for treatment of SJIA. Median drug
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survival was comparable for ANA, CAN and TCZ when
used as a first line biologic.
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